The first blog post for this year was on interchangeability. In it I announced that…
Cipla South AfricaJanuary 20, 2024
In the first post in this series on pharmaceutical specifications, I mentioned that characteristics or…
Cipla South AfricaSeptember 1, 2023
Vienna, June 14, 2023 – The COVID-19 pandemic demonstrated the critical importance of resilient global…
Cipla South AfricaJuly 7, 2023
Several attempts have been made in the past ten years or so to establish a…
Cipla South AfricaJune 30, 2023
Nitrosoamine impurities have been a major concern to regulators and the pharmaceutical industry since 2018…
Cipla South AfricaMay 5, 2023
It is widely acknowledged that South Africa needs its own biosimilar manufacturing industry, and in…
Cipla South AfricaMarch 30, 2023
The SAHPRA, like many other developing country regulatory authorities with capacity constraints, has implemented in…
Cipla South AfricaMarch 2, 2023
After months of writing about it, and even raising the issue among regulatory stakeholders, SAHPRA…
Cipla South AfricaFebruary 23, 2023
I have written before about insulin – a simple biologic with arguably the least stringent…
Cipla South AfricaDecember 8, 2022
https://www.youtube.com/watch?v=ITO49g5BO9A Non-biological complex drugs (NBCDs) represent a class of diverse synthetic drugs midway between conventional…
Cipla South AfricaNovember 9, 2022
From the desk of Henry Leng – In my post of three months ago (published…
Cipla South AfricaSeptember 14, 2022
